Brian K Link

Title: Brian K Link: Innovator in Bispecific Antibodies

Introduction

Brian K Link is a notable inventor based in Coralville, IA (US), recognized for his contributions to the field of biotechnology. He holds 2 patents that focus on innovative therapeutic solutions for malignant B-cells. His work has significant implications for the treatment of B-cell lymphoma, showcasing his expertise in antibody engineering.

Latest Patents

One of his latest patents is titled "Humanized antibodies against CD3." This invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. Furthermore, it provides therapeutic and diagnostic methods employing these antibodies. Another significant patent is "Bispecific antibody effective to treat B-cell lymphoma and cell line," which shares similar features and applications as the previous patent, emphasizing the potential of bispecific antibodies in targeted cancer therapies.

Career Highlights

Throughout his career, Brian K Link has worked with prominent companies in the biotechnology sector, including Protein Design Labs, Inc. and PDL Biopharma, Inc. His experience in these organizations has contributed to his development as an innovator in the field.

Collaborations

Brian has collaborated with esteemed colleagues such as George J Weiner and Roger Gingrich, further enhancing his research and development efforts in bispecific antibodies.

Conclusion

Brian K Link's innovative work in bispecific antibodies represents a significant advancement in the treatment of B-cell malignancies. His patents and collaborations reflect his commitment to improving therapeutic options for patients.